High-Performance Piezoelectric Energy Harvesters and Their Applications

The last decade has witnessed significant advances in energy harvesting technologies as a possible alternative to provide a continuous power supply for small, low-power devices in applications, such as wireless sensing, data transmission, actuation, and medical implants. Piezoelectric energy harvesting (PEH) has been a salient topic in the literature and has attracted widespread attention from researchers due to its advantages of simple architecture, high power density, and good scalability. This paper presents a comprehensive review on the state-of-the-art of piezoelectric energy harvesting. Various key aspects to improve the overall performance of a PEH device are discussed, including basic fundamentals and configurations, materials and fabrication, performance enhancement mechanisms, applications, and future outlooks.

A comprehensive review on piezoelectric energy harvesting technology: Materials, mechanisms, and applications

Energy harvesting technologies have been explored by researchers for more than two decades as an alternative to conventional power sources (e.g. batteries) for small-sized and low-power electronic devices. The limited life-time and necessity for periodic recharging or replacement of batteries has been a consistent issue in portable, remote, and implantable devices. Ambient energy can usually be found in the form of solar energy, thermal energy, and vibration energy. Amongst these energy sources, vibration energy presents a persistent presence in nature and manmade structures. Various materials and transduction mechanisms have the ability to convert vibratory energy to useful electrical energy, such as piezoelectric, electromagnetic, and electrostatic generators. Piezoelectric transducers, with their inherent electromechanical coupling and high power density compared to electromagnetic and electrostatic transducers, have been widely explored to generate power from vibration energy sources. A topical review of piezoelectric energy harvesting methods was carried out and published in this journal by the authors in 2007. Since 2007, countless researchers have introduced novel materials, transduction mechanisms, electrical circuits, and analytical models to improve various aspects of piezoelectric energy harvesting devices. Additionally, many researchers have also reported novel applications of piezoelectric energy harvesting technology in the past decade. While the body of literature in the field of piezoelectric energy harvesting has grown significantly since 2007, this paper presents an update to the authors' previous review paper by summarizing the notable developments in the field of piezoelectric energy harvesting through the past decade.

https://iopscience.iop.org/article/10.1088/1361-665X/ab36e4/pdf

A review of energy harvesting using piezoelectric materials: state-of-the-art a decade later (2008–2018)

A comprehensive review on the state-of-the-art of piezoelectric energy harvesting

Energy harvesting technologies in roadway and bridge for different applications – A comprehensive review

Feasible integration in asphalt of piezoelectric cymbals for vibration energy harvesting

Membrane transporters play a significant role in facilitating transmembrane drug movement. For new pharmacological agents, it is important to evaluate potential interactions (e.g., substrate specificity and/or inhibition) with human transporters that may affect their pharmacokinetics, efficacy, or toxicity. Bilastine is a new nonsedating H₁ antihistamine indicated for the treatment of allergic rhinoconjunctivitis and urticaria. The in vitro inhibitory effects of bilastine were assessed on 12 human transporters: four efflux [multidrug resistance protein 1 (MDR1) or P-glycoprotein, breast cancer resistance protein (BCRP), multidrug resistance associated protein 2 (MRP2), and bile salt export pump) and eight uptake transporters (sodium taurocholate cotransporting polypeptide, organic cation transporter (OCT)1, organic anion transporter (OAT)1, OAT3, OCT2, OATP2B1, OATP1B1, and OATP1B3). Only mild inhibition was found for MDR1-, OCT1-, and OATP2B1-mediated transport of probe substrates at the highest bilastine concentration assayed (300 μM; half-maximal inhibitory concentration: ≥300 μM). Bilastine transport by MDR1, BCRP, OAT1, OAT3, and OCT2 was also investigated in vitro. Only MDR1 active transport of bilastine was relevant, whereas it did not appear to be a substrate of OCT2, OAT1, or OAT3, nor was it transported substantially by BCRP. Drug-drug interactions resulting from bilastine inhibition of drug transporters that would be generally regarded as clinically relevant are unlikely. Additionally, bilastine did not appear to be a substrate of human BCRP, OAT1, OAT3, or OCT2 and thus is not a potential victim of inhibitors of these transporters. On the other hand, based on in vitro evaluation, clinically relevant interactions with MDR1 inhibitors are anticipated.

Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems.

Knowledge of the biotransformation of oral H1 antihistamines is clinically important because it can define their pharmacokinetic profile through possible effects on absorption (i.e., first-pass metabolism) and elimination. Further, clinically significant interactions with inhibitors of cytochrome P450 (CYP) have previously been reported for drugs of this therapeutic group, such as terfenadine and astemizole, indicating the possibility of drug-drug interactions involving agents that share the same metabolic pathway. The aim of this article was to review the preclinical testing of a new antihistamine (i.e., bilastine) in terms of its biotransformation in various animal species, including humans, and to evaluate its potential for possible drug-drug interactions involving the CYP system. A wide array of preclinical experiments were reviewed, all of which demonstrated that bilastine undergoes minimal metabolism in all species tested to date, including humans. Further, bilastine did not interact significantly, ...

An overview of bilastine metabolism during preclinical investigations

Modern pharmacometrics can integrate and leverage all prior proprietary and public knowledge. Such methods can be used to scale across species or comparators, perform clinical trial simulation across alternative designs, confirm hypothesis and potentially reduce development burden, time and costs. Crucial yet typically lacking in integration is the pre-clinical stage. Prediction of PK in man, using in vitro and in vivo studies in different animal species, is increasingly well theorized but could still find wider application in drug development. The aim of the present work was to explore methods for bridging pharmacokinetic knowledge from animal species (i.v. and p.o.) and man (p.o.) into i.v. in man using the antihistamine drug bilastine as example. A model, predictive of i.v. PK in man, was developed on data from two pre-clinical species (rat and dog) and p.o. in man bilastine trials performed earlier. In the knowledge application stage, two different approaches were used to predict human plasma concentration after i.v. of bilastine: allometry (several scaling methods) and a semi-physiological method. Both approaches led to successful predictions of key i.v. PK parameters of bilastine in man. The predictive i.v. PK model was validated using later data from a clinical study of i.v. bilastine. Introduction of such knowledge in development permits proper leveraging of all emergent knowledge as well as quantification-based exploration of PK scenario, e.g. in special populations (pediatrics, renal insufficiency, comedication). In addition, the methods permit reduction or elimination and certainly optimization of learning trials, particularly those concerning alternative off-label administration routes.

Ana Gonzalo

Papers

Feasible integration in asphalt of piezoelectric cymbals for vibration energy harvesting

Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems.

An overview of bilastine metabolism during preclinical investigations

Integration of preclinical and clinical knowledge to predict intravenous PK in human: Bilastine case study

Toxicokinetics of bilastine in animals: The effects of the dose and route of administration